RBM39 and acute myeloid leukemia: A recent study using CRISPR/Cas9 screening demonstrated that complete loss of RBM39 suppresses AML growth both in vitro and in vivo, while pharmacologic RBM39 degradation results in broad anti-leukemic effects and preferential lethality of spliceosomal mutant AML20.